anti dapi Search Results


98
Vector Laboratories id source h1200

Id Source H1200, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/id source h1200/product/Vector Laboratories
Average 98 stars, based on 1 article reviews
id source h1200 - by Bioz Stars, 2026-06
98/100 stars
  Buy from Supplier

96
Vector Laboratories dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Dapi, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dapi/product/Vector Laboratories
Average 96 stars, based on 1 article reviews
dapi - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

90
Beijing Solarbio Science fluorescence quencher containing dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Fluorescence Quencher Containing Dapi, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fluorescence quencher containing dapi/product/Beijing Solarbio Science
Average 90 stars, based on 1 article reviews
fluorescence quencher containing dapi - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Promega prolong gold anti fade reagent containing dapi staining
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Prolong Gold Anti Fade Reagent Containing Dapi Staining, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prolong gold anti fade reagent containing dapi staining/product/Promega
Average 90 stars, based on 1 article reviews
prolong gold anti fade reagent containing dapi staining - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Beijing Solarbio Science anti-fluorescent attenuation sealer containing dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Anti Fluorescent Attenuation Sealer Containing Dapi, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-fluorescent attenuation sealer containing dapi/product/Beijing Solarbio Science
Average 90 stars, based on 1 article reviews
anti-fluorescent attenuation sealer containing dapi - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Maravai LifeSciences dapi containing anti-fluorescence quencher
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Dapi Containing Anti Fluorescence Quencher, supplied by Maravai LifeSciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dapi containing anti-fluorescence quencher/product/Maravai LifeSciences
Average 90 stars, based on 1 article reviews
dapi containing anti-fluorescence quencher - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Carl Roth GmbH anti-quenching medium rotimount with dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Anti Quenching Medium Rotimount With Dapi, supplied by Carl Roth GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-quenching medium rotimount with dapi/product/Carl Roth GmbH
Average 90 stars, based on 1 article reviews
anti-quenching medium rotimount with dapi - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Quartett GmbH aqueous mounting solution containing dapi (4',6-diamidino-2-phenylindole; protaqs mountfluor anti-fading)
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Aqueous Mounting Solution Containing Dapi (4',6 Diamidino 2 Phenylindole; Protaqs Mountfluor Anti Fading), supplied by Quartett GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aqueous mounting solution containing dapi (4',6-diamidino-2-phenylindole; protaqs mountfluor anti-fading)/product/Quartett GmbH
Average 90 stars, based on 1 article reviews
aqueous mounting solution containing dapi (4',6-diamidino-2-phenylindole; protaqs mountfluor anti-fading) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
MetaSystems inc anti-fade dapi
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Anti Fade Dapi, supplied by MetaSystems inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-fade dapi/product/MetaSystems inc
Average 90 stars, based on 1 article reviews
anti-fade dapi - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Beijing Solarbio Science anti-fluorescence quenching tablet containing 4', 6-diamidino-2-phenylindole
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Anti Fluorescence Quenching Tablet Containing 4', 6 Diamidino 2 Phenylindole, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-fluorescence quenching tablet containing 4', 6-diamidino-2-phenylindole/product/Beijing Solarbio Science
Average 90 stars, based on 1 article reviews
anti-fluorescence quenching tablet containing 4', 6-diamidino-2-phenylindole - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Beijing Solarbio Science dapi combined with an anti-fluorescent bursting agent
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Dapi Combined With An Anti Fluorescent Bursting Agent, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dapi combined with an anti-fluorescent bursting agent/product/Beijing Solarbio Science
Average 90 stars, based on 1 article reviews
dapi combined with an anti-fluorescent bursting agent - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Beijing Solarbio Science anti-fluorescence attenuators (containing dapi)
Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) <t>%</t> <t>GFAP+</t> cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% <t>GFAP/DAPI+</t> cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).
Anti Fluorescence Attenuators (Containing Dapi), supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-fluorescence attenuators (containing dapi)/product/Beijing Solarbio Science
Average 90 stars, based on 1 article reviews
anti-fluorescence attenuators (containing dapi) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Journal: eLife

Article Title: Adult-born neurons facilitate olfactory bulb pattern separation during task engagement

doi: 10.7554/eLife.33006

Figure Lengend Snippet:

Article Snippet: antibody , DAPI , Vector Labs , ID_source:H1200 , .

Techniques: Transfection, Plasmid Preparation, Software

Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) % GFAP+ cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% GFAP/DAPI+ cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).

Journal: bioRxiv

Article Title: Computational Identification of Ligand-Receptor Pairs that Drive Human Astrocyte Development

doi: 10.1101/2022.05.31.491513

Figure Lengend Snippet: Ligand activity depends on hCO developmental stage. A . Following a 30-day exposure in hCOs, mouse-identified ligands 1-5 do not significantly modulate astrocyte or neuronal gene signatures (N.S. p = .781, Mann Whitney U) (n = 8 control organoids, 12 ligand-exposed organoids). B . Human-identified ligands 6-10 significantly increase expression of astrocyte gene signatures and decrease expression of neuronal genes (p = .002, Mann Whitney U). C . Heatmap of neuronal and astrocyte gene expression following ligand exposure. Classic signature genes for each population are highlighted. D . Schematic of proposed timeline of the gliogenic switch in organoid cultures. E . Variability of gliogenic switch in hCOs. 10 separate hCO differentiations (n = 5 hiPSC lines) were assayed for (1) % GFAP+ cells by IHC, (2) GFAP mRNA by qPCR, and (3) number of cells bound to HepaCAM+ immunopanning plate at 10-day intervals from days 70-110 in culture. Thresholds were set for each assay to determine that gliogenesis had begun. These include >5% GFAP/DAPI+ cells for IHC (top panel), a CT cutoff <30 for GFAP qPCR (middle panel), and >10,000 HepaCAM immunopanned astrocyte per organoid (lower panel). F . Representative GFAP and TUJ1 staining of day 40, day 100, day 200, and day 300 hCOs. Scale bar =100 µm, G-I . Result of ligand exposures (6-10) at different stages of hCO culture. Readouts are fold change of astrocyte and neuronal gene signatures compared to control hCOs using RNA-seq. (N.S. p = .643, ***p<.0001, Mann Whitney U) (n = 6-8 control organoids and 6-12 experimental organoids). J-K . Expression of target receptors for NicheNet-predicted ligands 6-10 throughout hCO development (***p<.0001, ***p<.0001, *p = .013, Mann Whitney U).

Article Snippet: Antibodies used were DAPI (in VECTASHEILD, Vector Laboratories, Cat. H-1500), GFAP (DAKO, Cat. Z0334, dilution 1:1500), and Ki67 (BD, Cat. b550609, dilution 1:50).

Techniques: Activity Assay, MANN-WHITNEY, Expressing, Staining, RNA Sequencing Assay

Impact of candidate ligand exposures on fetal astrocytes. A . GW 17-20 cortices were immunopanned for CD49f+ immature astrocytes, which were cultured for 10 days in the presence or absence of the ligand cocktail. B . Astrocyte and neuronal gene signatures assessed by RNA-seq of CD490f+ cells. Fold change represents expression in ligand conditions vs control media (p < .001, Mann Whitney U). C . GFAP+ cell process traces from ligand-exposed and control CD49f+ fetal cells. Scale bar = 50 µm. D . GFAP+ cell process quantification. Primary branches extend from the nucleus. Secondary branches extend from primary branches. Boundary size is the area (x 10 3 µm 2 ) of the image field that one cell occupies. (*p<.01, **p<.001, *** p<.0001, Mann Whitney U). E . Timeline of EdU exposure. Fetal astrocytes were cultured for 8 days after purification with ligand exposure from days 1-7. EdU added at day 1 until duration of experiment. F . No significant change in percent of EdU+ nuclei between control and ligand-exposed cells. G . Representative images of DAPI and EdU+ cells after 8 days in culture.

Journal: bioRxiv

Article Title: Computational Identification of Ligand-Receptor Pairs that Drive Human Astrocyte Development

doi: 10.1101/2022.05.31.491513

Figure Lengend Snippet: Impact of candidate ligand exposures on fetal astrocytes. A . GW 17-20 cortices were immunopanned for CD49f+ immature astrocytes, which were cultured for 10 days in the presence or absence of the ligand cocktail. B . Astrocyte and neuronal gene signatures assessed by RNA-seq of CD490f+ cells. Fold change represents expression in ligand conditions vs control media (p < .001, Mann Whitney U). C . GFAP+ cell process traces from ligand-exposed and control CD49f+ fetal cells. Scale bar = 50 µm. D . GFAP+ cell process quantification. Primary branches extend from the nucleus. Secondary branches extend from primary branches. Boundary size is the area (x 10 3 µm 2 ) of the image field that one cell occupies. (*p<.01, **p<.001, *** p<.0001, Mann Whitney U). E . Timeline of EdU exposure. Fetal astrocytes were cultured for 8 days after purification with ligand exposure from days 1-7. EdU added at day 1 until duration of experiment. F . No significant change in percent of EdU+ nuclei between control and ligand-exposed cells. G . Representative images of DAPI and EdU+ cells after 8 days in culture.

Article Snippet: Antibodies used were DAPI (in VECTASHEILD, Vector Laboratories, Cat. H-1500), GFAP (DAKO, Cat. Z0334, dilution 1:1500), and Ki67 (BD, Cat. b550609, dilution 1:50).

Techniques: Cell Culture, RNA Sequencing Assay, Expressing, MANN-WHITNEY, Purification